Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has provided an announcement.
Biocytogen Pharmaceuticals announced a voluntary share repurchase plan, approved at its 2024 AGM, to buy back up to 11,078,192 H Shares, representing 10% of its H Shares and 2.77% of its total issued share capital, using internal funds up to HK$50 million over the next 24 months. The repurchased shares may be held as Treasury Shares or used for employee share awards, with the company appointing Kastle Limited to manage the repurchase and CMB Wing Lung (Trustee) Limited to oversee the Share Award Scheme, all while adhering to regulatory requirements and market conditions.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development of innovative drugs and biotechnological solutions.
Average Trading Volume: 366,347
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.53B
Learn more about 2315 stock on TipRanks’ Stock Analysis page.